×
About Us
Overview
Our Leadership
Board of Directors
Scientific Advisory Board
Cell Manufacturing Advisory Board
Strategic Partners
Technology
Allogeneic Cell Therapy Platform
Oncolytic Virus Combinations
CD30 CAR-T Cell Therapy
Manufacturing
Pipeline
TT11X Allogeneic CD30 CAR EBVSTs
TT16 HER2 CAR Ts + CAdVEC
TT11 CD30 CAR Ts
TT11 CD30 CAR Ts + Nivolumab
Expanded Access
Scientific Publications
Investors & Media
Press Releases & Events
Interviews
Careers
Contact Us
×
What are you looking for?
Search for:
About Us
Overview
Our Leadership
Board of Directors
Scientific Advisory Board
Cell Manufacturing Advisory Board
Strategic Partners
Technology
Allogeneic Cell Therapy Platform
Oncolytic Virus Combinations
CD30 CAR-T Cell Therapy
Manufacturing
Pipeline
TT11X Allogeneic CD30 CAR EBVSTs
TT16 HER2 CAR Ts + CAdVEC
TT11 CD30 CAR Ts
TT11 CD30 CAR Ts + Nivolumab
Expanded Access
Scientific Publications
Investors & Media
Press Releases & Events
Interviews
Careers
Contact Us
Our Scientific Co-Founder Explains The Science Behind Virus-Specific T Cells
by
tessathe
on
February 27, 2019
in
news-videos
<< Back to Press Releases & Events
Previous Reading
Distinguished breast cancer expert, Dr. George W. Sledge, Jr., M.D., joins our Board
Next Reading
Biopharma veteran, Jeffrey H. Buchalter is our newest independent board director
